PTEN Mutation in Cancer
Tumor SuppressorPhosphatase and Tensin Homolog
PTEN is a phosphatase that negatively regulates the PI3K/AKT pathway. Loss of PTEN function leads to uncontrolled cell growth and is common in endometrial, prostate, and brain cancers.
What Is PTEN?
PTEN (Phosphatase and Tensin Homolog) is a dual-specificity phosphatase that acts as one of the most important tumor suppressors in human biology. Its primary function is to dephosphorylate PIP3, directly antagonizing the PI3K/AKT/mTOR signaling pathway. By keeping this growth-promoting pathway in check, PTEN serves as a critical brake on cell proliferation, survival, and metabolism. When PTEN is lost or inactivated, the PI3K pathway becomes hyperactive.
PTEN Mutations in Cancer
PTEN is among the most commonly deleted or mutated tumor suppressor genes in cancer, with alterations found in approximately 8-10% of all tumors (higher when including epigenetic silencing and copy number loss). PTEN mutations are most prevalent in endometrial cancer (~65%), glioblastoma (~30-40%), prostate cancer (~20-40%), and melanoma (~10-15%). Unlike oncogenes with hotspot mutations, PTEN alterations are scattered throughout the gene and include point mutations, deletions, frameshifts, and promoter methylation.
Clinical Significance and Cowden Syndrome
Somatic PTEN loss is associated with aggressive disease features and therapeutic resistance in many cancer types. Germline PTEN mutations cause PTEN hamartoma tumor syndromes, most notably Cowden syndrome, characterized by multiple hamartomas and a markedly increased risk of breast, thyroid, endometrial, and other cancers. PTEN status is increasingly used to guide therapy: PTEN loss may predict sensitivity to PI3K/AKT/mTOR pathway inhibitors and resistance to certain immunotherapies.
Morphological Associations
PTEN-deficient tumors display characteristic histological features. In endometrial cancer, PTEN loss associates with endometrioid histology and lower-grade disease. In prostate cancer, PTEN deletion correlates with higher Gleason score, larger tumor volume, and cribriform morphology. In glioblastoma, PTEN loss is associated with more diffuse infiltrative patterns. HistoAtlas quantifies these morphological differences across 33 TCGA cancer types using computational analysis of whole slide images.
Frequently Asked Questions
What is a PTEN mutation?
A PTEN mutation is a change in the PTEN gene that inactivates the PTEN phosphatase protein, removing a critical brake on the PI3K/AKT growth-signaling pathway. PTEN is one of the most commonly altered tumor suppressors in cancer, found in ~65% of endometrial cancers, ~30% of glioblastomas, and ~20% of prostate cancers.
Is PTEN mutation hereditary?
Most PTEN mutations in cancer are somatic (acquired). However, inherited germline PTEN mutations cause PTEN hamartoma tumor syndromes, including Cowden syndrome, which carries significantly increased risks for breast cancer (85% lifetime risk), thyroid cancer (35%), and endometrial cancer (28%). Genetic testing is recommended for individuals meeting clinical criteria.
What is PTEN mutation Cowden syndrome?
Cowden syndrome is a hereditary condition caused by germline PTEN mutations. It is characterized by multiple hamartomas (benign growths) and a dramatically increased lifetime risk of breast, thyroid, endometrial, kidney, and colorectal cancers. Cowden syndrome patients require intensive cancer surveillance starting in their 20s.
Does PTEN mutation affect survival?
PTEN loss is generally associated with more aggressive disease and worse outcomes, though the impact varies by cancer type. In prostate cancer, PTEN deletion correlates with higher-grade disease and shorter time to metastasis. In glioblastoma, PTEN status is prognostic. HistoAtlas provides survival curves comparing PTEN-mutant vs wild-type tumors across 33 TCGA cancer types.